Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, a small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The study showed reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, providing strong evidence for the drug’s biological activity in Wilson’s disease.
Wilson’s disease is a rare genetic disorder characterized by copper accumulation in the liver and brain, leading to severe liver damage and neurological symptoms. Current treatments focus on chelation therapy to remove excess copper, but they often have limited efficacy or significant side effects. Telomir-Zn’s mechanism targets intracellular metal homeostasis and redox balance, offering a novel approach that could address underlying disease pathology.
The findings expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. The positive results in Wilson’s disease underscore the potential versatility of Telomir-Zn beyond oncology, tapping into fundamental epigenetic and metabolic mechanisms implicated in degenerative diseases.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing therapeutics targeting epigenetic and metabolic mechanisms in cancer, aging, and degenerative diseases. The publication in a peer-reviewed journal adds credibility to the company’s platform and may attract further interest from the scientific and investment communities.
The full press release is available at https://ibn.fm/fOSNo. For more information about Telomir Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TELO.
